课题基金 / 基金详情

A PHASE I STUDY OF THE GARFT INHIBITOR AG2034 IN PATIENTS WITH ADVANCED CANCER

A PHASE I STUDY OF THE GARFT INHIBITOR AG2034 IN PATIENTS WITH ADVANCED CANCER
GARFT 抑制剂 AG2034 在晚期癌症患者中的 I 期研究
批准号：
6113677
负责人：
DARCY V SPICER
金额：
$3.56万
依托单位：
UNIVERSITY OF SOUTHERN CALIFORNIA
依托单位国家：
美国
项目类别：
财政年份：
1998
资助国家：
美国
项目状态：
已结题
起止时间：
1998-12-01 至 1999-11-30
来源：
https://reporter.nih.gov/project-details/6113677
关键词：
clinical research clinical trial phase I dosage drug screening /evaluation enzyme inhibitors folate human subject human therapy evaluation hydroxymethyltransferases neoplasm /cancer chemotherapy pharmacokinetics purine /pyrimidine metabolism purines

项目摘要

项目成果

DARCY V SPICER的其他基金

相似基金

相关文献

中文摘要
翻译
GARFT是嘌呤从头合成途径中必需的酶。AG2034是一种新型的GARFT抑制剂。本研究将评估AG2034静脉给药给晚期癌症患者的安全性和剂量耐受性。利用叶酸和嘌呤状态和药物代谢产物的细胞保留指标研究AG2034的药代动力学和药效学。任何抗肿瘤作用都将被记录。将确定最大剂量和剂量限制性毒性。
英文摘要
GARFT is an enzyme essential in the pathway for de novo synthesis of purines. AG2034 is a novel inhibitor of GARFT. This study will evaluate the safety and dose tolerance of AG2034 when given IV to patients with advanced cancer. The pharmacokinetics and pahrmacodynamics for AG2034 using indicator of folate and purine status and cellular retention of drug-matabolites will be studied. Any antitumor effects will be documented. The maximum dose and dose-limiting toxicities will be determined.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
SCCISARS 2: An e-Solution to Protect Human Subjects
A PHASE I STUDY OF THE GARFT INHIBITOR AG2034 IN PATIENTS WITH ADVANCED CANCER
PHASE II RANDOMIZED STUDY OF PACLITAXEL VS PACLITAXEL+PSC833 FOR BREAST CANCER
PHASE II RANDOMIZED STUDY OF PACLITAXEL VS PACLITAXEL+PSC833 FOR BREAST CANCER
海外基金